Latest Articles about PRGO

Earnings Miss at Perrigo - Analyst Blog

Zacks Equity Research — Tue, 07 May 2013 20:24:49 Z

Perrigo Company 's ( PRGO ) third quarter fiscal 2013 (ended Mar 30, 2013) earnings of $1.42 per share fell short of the Zacks Consensus Estimate by 2 cents. Lower-than-expected revenues

Pre-Market Earnings Report for May 7, 2013 : EMR, EOG, DTV, HCN, FE, DISCA, PRGO, CHTR, HFC, NRG, TAP, HSIC

NASDAQ.com News — Tue, 07 May 2013 00:00:04 Z

The following companies are expected to report earnings prior to market open on 05/07/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Emerson Electric Company

Perrigo Likely to Report In Line Earnings - Analyst Blog

Mark Vickery — Mon, 06 May 2013 23:23:50 Z

We expect Perrigo Company ( PRGO ) to report in line third quarter fiscal 2013 results before the opening bell on May 7. The company's fiscal year ends on the last Saturday of Jun every

Covidien's 2Q Earnings Beat - Analyst Blog

Zacks Equity Research — Fri, 26 Apr 2013 23:40:01 Z

Covidien plc. 's ( COV ) adjusted earnings per share (EPS) from continuing operations of $1.12 for the second quarter of fiscal 2013 beat the Zacks Consensus Estimate of $1.10 by 1.8%.

Stryker's 1Q Earnings Beat Est.; Sales Lag - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 23:13:14 Z

Stryker Corporation 's ( SYK ) adjusted earnings per share (EPS) of $1.03 increased 4.0% year over year in the first quarter of 2013. It beat the Zacks Consensus Estimate by 2 cents.

Covidien Collaborates with VIDA - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 22:10:42 Z

International healthcare major, Covidien plc ( COV ) has inked an agreement with leading pulmonary imaging software service provider, VIDA Diagnostics. As per the agreement, Covidien will

St. Jude's 1Q Earnings In Line - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 21:20:41 Z

St. Jude Medical 's ( STJ ) first-quarter adjusted earnings per share of 92 cents were in line with the Zacks Consensus Estimate and transcended the year-ago earnings of 86 cents.

Perrigo Touches 52-Week High - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 17:23:05 Z

Shares of Perrigo Company ( PRGO ) soared to a 52-week high of $120.94 during the course of the trading session on Apr 2, 2013 buoyed by a series of positive developments. The closing price

Perrigo Buys Velcera - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 01:24:35 Z

The spate of acquisitions at Perrigo Company ( PRGO ) continued with its purchase of companion animal health company, Velcera, Inc. for approximately $160 million in cash. The deal, which

Perrigo Ships Mucinex Generic - Analyst Blog

Zacks Equity Research — Thu, 21 Mar 2013 23:34:59 Z

Perrigo Company ( PRGO ) recently commenced shipping its generic version of Adams Respiratory Therapeutics' drug Mucinex (600mg extended-release tablets). Adams Respiratory Therapeutics is

Perrigo Company (PRGO) Ex-Dividend Date Scheduled for February 27, 2013

NASDAQ.com News — Mon, 25 Feb 2013 19:00:05 Z

Perrigo Company ( PRGO ) will begin trading ex-dividend on February 27, 2013. A cash dividend payment of $0.09 per share is scheduled to be paid on March 19, 2013. Shareholders who purchased

Patent Challenge from Perrigo - Analyst Blog

Zacks Equity Research — Thu, 21 Feb 2013 03:10:01 Z

Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its

Perrigo in Expansion Mode - Analyst Blog

Zacks Equity Research — Wed, 13 Feb 2013 02:15:01 Z

Perrigo Company ( PRGO ) recently announced that it is set to acquire a UK-based privately held pharmaceutical company, Rosemont Pharmaceuticals Ltd. and has entered into a definitive

FDA Clears Testosterone Gel - Analyst Blog

Zacks Equity Research — Thu, 07 Feb 2013 03:40:01 Z

Recently, Perrigo Company ( PRGO ) announced that it has gained approval from the US Food and Drug Administration (FDA) pertaining to its New Drug Application (NDA) for testosterone gel 1%.

Market Close Report: NASDAQ Composite index closes at 3,179.10 up 36.97 points

NASDAQ.com News — Sat, 02 Feb 2013 02:45:13 Z

Friday's session closes with the NASDAQ Composite Index at 3,179.10. The total shares traded for the NASDAQ was over 1.97 billion. Advancers stocks led declining by 2.6 to 1 ratio. There were